<DOC>
	<DOCNO>NCT02472366</DOCNO>
	<brief_summary>A phase 4 trial evaluate effect safety ILUVIEN chronic DME patient insufficiently responsive available therapy .</brief_summary>
	<brief_title>A Non-Randomized , Open-Label , Single Center Phase 4 Study Effect Safety ILUVIEN® Chronic Diabetic Macular Edema Patients Considered Insufficiently Responsive Available Therapies ( Laser , Anti-VEGF ) With Without Intravitreal Corticosteroid Therapy</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Fluocinolone Acetonide</mesh_term>
	<criteria>1 . Patients ≥18 year age , either sex sign informed consent / well inform treat physician . 2 . DME base investigator 's clinical evaluation demonstrate use fundoscopic photography spectral domain OCT. 3 . Mean central foveal thickness ( central subfield thickness ) ≥350 micron study eye measure use spectral domain OCT. 4 . Vision impairment ( 20/60 20/400 use Snellen visual acuity equivalent ) relate DME . 5 . Previous treatment study eye laser photocoagulation DME , include focal/grid panretinal , least 3 month prior screen visit ≥3 monthly antiVEGF treatment ( group 1 ) . 6 . Previous treatment study eye laser photocoagulation DME least 3 month prior screen visit ( group 2 ) treatment intraocular antiVEGF therapy possible . 7 . Patients consider insufficiently responsive prior therapy DME , define study physician . 1 . IOP &gt; 21 mmHg screening study eye . 2 . Historical rise IOP &gt; 25 mmHg follow treatment intravitreal corticosteroid study eye . 3 . Use ≥2 IOPlowering medication control IOP screening study eye . 4 . Patients vitreomacular traction DME opaque medium study eye . 5 . Patients severe proliferative diabetic retinopathy require pan retinal photocoagulation study eye . 6 . Pregnant breastfeeding . 7 . Patients diagnose active angiographic central vein ischaemia prior screen study eye . 8 . Patients receive pan retinal photocoagulation undergone cataract surgery 3 month prior study start date study eye . 9 . Patients contraindication accord current SPC : 1 . The presence preexist glaucoma . 2 . Active suspect ocular periocular infection . 3 . The patient hypersensitive active agent one excipients .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>